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In this issue of the Polish Journal of Neurology and Neuro-
surgery, we introduce a new form of publication of collected 
papers regarding one topic. This we call a ‘leading topic’. As 
guest editors of this special series of papers, we would like 
to present selected papers regarding botulinum neurotoxin 
(BoNT) treatment in neurology.
Botulinum neurotoxin is a leading treatment option in 
many indications in neurology such as focal/segmental dys-
tonias (blepharospasm, Meige syndrome, cervical dystonia, 
writer’s cramp or spasmodic dysphonia), spasticity in children 
(cerebral palsy) and adults (post-stroke), overactive bladder, 
chronic migraine or hyperhidrosis and siallorhea (Tab. 1). 
The list of as-yet unlicensed or off-label indications is long 
and some examples will be discussed (Tab. 2). A PubMed 
database search using the key word ‘Botulinum toxin’ found 
10,568 records at the end of March 2021, making this treatment 
option a leading topic in neurology. 
There are three major botulinum neurotoxin type-A 
preparations according to the FDA (the US Food & Drug 
Administration) requirements: onabotulinumtoxinA (ONA-
-BoNT/A), abobotulinumtoxinA (ABO-BoNT/A), and 
incobotulinumtoxinA (INCO-BoNT/A). These have the 
trade names Botox®, Dysport® and Xeomin® respectively. 
Botulinum neuroxin type B (rhimabotulinumtoxinB) with 
the trade name Myobloc/Neurobloc® was intended to be used 
in secondary unresponsiveness to type-A with the formation 
of neutralising antibodies. The efficacy and safety of BoNT/A 
and B have been positively assessed and rated at level A or B 
(for different indications and preparations) by the American 
Academy of Neurology in its Task Force guidelines [1]. Their 
effectiveness has been confirmed in many open-label studies 
including ones also published in this journal, and indeed in 
this issue [2–5]. 
However, although this treatment has been offered to 
patients for the last 30 years, many unresolved problems and 
unmet needs remain.. One of them is the inability to make 
a direct comparison in terms of efficacy and the lack of a uni-
versal dose-ratio between different products. In two papers 
published in this issue, we have reviewed both the basic [6] 
and the clinical [7, 8] research in terms of bioequivalence of 
currently available preparations in major indications. Many 
of them are indirect, showing the overall results achieved with 
pre-established doses of different preparations. Direct compar-
isons were made difficult because of pre-fixed ratios, different 
methodologies, and the relatively low quality of studies. 
We have concluded that universal ratios between products 
cannot be therefore established. Methods of assessment of 
clinical efficacy differ between companies. Also the methodol-
ogies of studies published so far has been rather poor, based on 
laboratory or electrophysiological methods in healthy volun-
teers or small groups of patients. This is especially important, 
because new BoNT/A fomulations (e.g. daxibotulinumtoxinA, 
prabotulinumtoxinA) are now in clinical trials, and therefore 
a switch between products in future might be even more dif-
ficult. Switching from one preparation to another is common 
in clinical practice, as shown in many open label studies with 
long follow ups. Lengthy treatment is a risk factor for the 
formation of  neutralising antibodies, and therefore treatment 
regimens should respect optimal (not maximal) doses and 
intervals between injections [9].  
L E A D I N G  T O P I C
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Table 1. Licensed indications for BoNT/A in neurology and beyond (according to SPCs for all three types of BoNT/A) [36–38]
Indication ONA-BoNT/A ABO-BoNT/A INCO-BoNT/A
Cervical dystonia
Blepharospasm
Strabismus (> 5yrs old)
Hemifacial spasm
Upper limb spasticity (post-stroke)
Lower limb spasticity (post-stroke)
Spasticity in cerebral palsy (upper limbs)
Spasticity in cerebral palsy (lower limbs)
Overactive bladder
Detrusor hyperactivity in neurological conditions (MS, SCI) and 











































MS — multiple sclerosis; SCI — spino-cerebral injury; *not present in US SPC. 
For ONA-BoNT/A the term ‘Blepharospasm, hemifacial spasm and other associated dystonias’ is used in SPC. Therefore, there is no specific indication for laryngeal dystonia or oromandibular dystonia
Table 2. Off-label indications for BoNT/A in neurology and beyond [26, 29, 
32, 34, 35, 39–41]
Axial dystonia








Parkinson's Disease (jaw tremors, axial dystonia, rectal dystonia, freez-
ing of gait, camptocormia, striatal toe)







Gastroenterology (anal fissure, constipation, achalasia, oesophageal 




In conclusion, we should respect the specific doses rec-
ommended in the summary product characteristics of specific 
BoNT/A medications and take into consideration the dose 
modifiers as being body and muscle mass, dysphagia, and 
dyspnoea. In spasticity, treatment has to be adjusted to func-
tional impairment: if function is preserved, the dose should 
be decreased.
Cervical dystonia (CD) remains the most challenging 
indication due to its complexity and the need for life-long treat-
ment. The wide spectrum of motor and non-motor problems 
(recognised in recent years) was discussed also in our journal 
in 2020 [10, 11] and now we continue this topic in this issue 
[5, 12, 13]. We emphasise the unmet needs for this kind of treat-
ment: the as yet not widely used or accepted Col-Cap concept 
and the most frequent patterns,the lack of specific scales for 
this new classification, the need for standardised ultrasound/ 
/electromyographical guided injections (and scientific proof 
that they really are superior to anatomical landmarks), and 
the lack of standardised treatments of non-motor symptoms. 
The doses of BoNT/A in CD and spasticity were arbitrarally 
established in clinical trials. In this issue, an international group 
of authors present the results of a multicentre study showing 
real-life treatment where doses were lower than in published 
guidelines, presumably due to more precise injections under 
US guidance [13]. As there have been no studies published so 
far looking for the optimal dose per muscle, this is perhaps not 
the best, but still a valuable, way of showing the effectiveness of 
doses used in clinical practice in experienced centres. The choice 
of muscle should be adjusted to the specific pattern of CD. The 
number of involved muscles varies, usually between four and six. 
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We should respect the maximal dose in the summary product 
characteristics of all three BoNT/A preparations [14, 15].
Muscle hypertonia in cerebral palsy has been a licensed 
indication for BoNT/A for the last 25 years. The authors of 
the evidence-based review on efficacy and safety published 
in this issue have shown that all major BoNT/A preparations 
have been established to reduce hypertonia in both upper and 
lower extremities, with some conflicting evidence regarding 
function. There are no differences in treatment safety, with 
a low incidence of adverse events which are mostly temporary 
and mild. Similarly to dystonia and spasticity in adults, there 
is no universal ratio enabling the calculation of dose when 
switching between preparations [9].  
This long-term treatment is complementary to rehabilita-
tion with the use of physiotherapy, orthotics and casting. Al-
though BoNT/A treatment alone was positively assessed by the 
American Academy of Neurology and Child Neurology Society 
[16], almost a decade later there is still scant evidence regarding 
its comparative treatment with different rehabilitation methods 
and moderate with placebo [17]. In severe generalised hyperto-
nia, a multilevel approach is recommended by different centres. 
The unresolved issues are the length of time between injections, 
the overall time of treatment, and how to define functional 
improvement. All these unresolved problems are valid also for 
spasticity in adults. This is usually severe in more pronounced 
paresis, and therefore functional improvement in the form 
of the recovery of complex and precise limb movements is 
usually not possible [18]. Therefore, so-called ‘goal-attainment 
treatment’ is now preferred to establish realistic goals with the 
patients and their care-giver before injection [19]. New studies 
have focused on early (< 3 months) spasticity after stroke and 
combined treatment with physiotherapy, casting, and orthoses. 
So far the quality of evidence on combined treatment is low. 
This early treatment with BoNT is a promising approach, and 
may decrease the severity of spasticity in the following months 
or years. In the first three months, the neural component dom-
inates over the biomechanical one with the ability to influence 
plasticity and central motor learning  [20 –23]. Nevertheless, it 
requires further long-term studies to prove the concept.
In chronic migraine (CM), BoNT/A therapy is now an 
established and licensed indication (exclusively for ONA- 
-BoNT/A after the successful PREEMPT studies). Never-
theless, new licensed and emerging biological therapies with 
anti-CGRP anibodies (mAbs such as erenumab, fremane-
zumab, galcanezumab etc) have given rise to the problem of 
how to position them in clinical practice and reimbursement 
systems. There are no head-to-head studies between mAbs and 
BoNT/A. Those pivotal studies performed to license mAbs 
also differed in methodology with BoNT/A studies. Therefore, 
positioning should be based on indirect comparisons, expert 
consensus, and pharmacoeconomic considerations. Further 
comparative studies are needed.
The spectrum of potential clinical indications for BoNT 
is still growing, with treatment of sialorrhea being a newly 
licensed indication (exclusively for INCO-BoNT/A) [24]. 
There is also a growing number of so-called ‘off-label in-
dications’ such as: essential tremor (the systematic review 
published recently in our journal suggests that improvement 
is usually biased by muscle weakness) [25], focal tics, myo-
clonus, bruxism [26], neuropathic pain (due to diabetic or 
postherpetic neuropathy and of central origin) [27, 28] or 
even depression [29]. 
Not strictly neurological, but helpful in our patients’ in-
dications (published earlier, but discussed also in this issue) 
is megacolon following a stroke and successfully treated with 
BoNT/A [30, 31]. Botulinum toxin is used also in other gas-
troenterological indications for the treatment of anal fissure, 
constipation (puborectal muscle) in Parkinson’s Disease or 
achalasia and many other conditions, along with cosmetic 
purposes (e.g. to remove frown lines, wrinkles) that are not 
discussed here (Tab. 2) [32–35].
Botulinum toxin over the last 30 years has changed the 
treatment modalities in many neurological disorders or symp-
toms. We hope and believe that the story is not over.
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